Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.
10 June 2024 - 9:00PM
Business Wire
Access to Premier’s healthcare group purchasing organization
(GPO) expected to expand national market reach for Surmodics
endovascular thrombectomy solutions.
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical
device and in vitro diagnostic technologies, today announced it has
been awarded a group purchasing agreement for thrombectomy products
with Premier, Inc. Effective June 1, 2024, the new agreement allows
Premier members, at their discretion, to take advantage of special
pricing and terms pre-negotiated by Premier for Surmodics Pounce™
and Pounce™ Venous Thrombectomy Systems.
“This is an exciting development for Surmodics,” said Gary
Maharaj, President and Chief Executive Officer of Surmodics. “Our
Pounce Arterial and Venous Thrombectomy Systems offer physicians
simplicity and procedural efficiency to remove arterial and venous
clot without the need for capital equipment. We are confident that
our portfolio of thrombectomy systems will contribute meaningfully
to high-quality, cost-effective care throughout the Premier
hospital alliance.”
The Surmodics thrombectomy portfolio comprises fully mechanical,
non-aspiration endovascular systems designed to promptly remove
soft or hardened blood clots from peripheral arteries (Pounce
Thrombectomy and Pounce Low-Profile [LP] Thrombectomy Systems) or
peripheral veins (Pounce Venous Thrombectomy System). Surmodics
thrombectomy systems, which do not require capital equipment, are
designed to minimize the need for physicians to remove clots using
thrombolytic drugs, a treatment that typically requires overnight
admission to an intensive care unit.
Premier is a leading healthcare improvement company, uniting an
alliance of more than 4,350 U.S. hospitals and 300,000 other
providers to transform healthcare. With integrated data and
analytics, collaboratives, supply chain solutions, and advisory and
other services, Premier enables better care and outcomes at a lower
cost.
About Surmodics, Inc.
Surmodics is a leading provider of performance coating
technologies for intravascular medical devices and chemical and
biological components for in vitro diagnostic immunoassay tests and
microarrays. Surmodics also develops and commercializes highly
differentiated vascular intervention medical devices that are
designed to address unmet clinical needs and engineered to the most
demanding requirements. This key growth strategy leverages the
combination of the Company’s expertise in proprietary surface
modification and drug-delivery coating technologies, along with its
device design, development, and manufacturing capabilities. The
Company’s mission is to improve the detection and treatment of
disease. Surmodics is headquartered in Eden Prairie, Minnesota. For
more information, visit www.surmodics.com. The content of
Surmodics’ website is not part of this press release or part of any
filings that the company makes with the Securities and Exchange
Commission.
About Surmodics thrombectomy products
Surmodics’ Pounce Thrombectomy platform devices are intended for
the non-surgical removal of thrombi and emboli from the peripheral
arterial vasculature. The Pounce LP Thrombectomy System is
indicated for use in vessels ranging from 2 mm to 4 mm in diameter,
sizes typical of vessels found below the knee. The Pounce LP System
complements the original Pounce Thrombectomy System, introduced in
2021, which is indicated for use in vessels 3.5 mm to 6 mm in
diameter.
The Pounce Venous System is indicated for mechanical de-clotting
and controlled and selective infusion of physician-specified
fluids, including thrombolytics, in the peripheral vasculature. The
Pounce Venous System is indicated for use in vessels 6 mm to 16 mm
in diameter. The Pounce Venous Systems may be used with the Pounce
Sheath (12 Fr), which is intended to introduce therapeutic or
diagnostic devices into the vasculature.
For more information on Pounce thrombectomy products, visit
www.pouncesystem.com and www.pouncevenous.com.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements.
Statements that are not historical or current facts, including
statements regarding the expectation that access to Premier GPO
members will expand the national market reach for Surmodics
endovascular thrombectomy solutions, the expectation that
Surmodics' portfolio of thrombectomy devices will contribute
meaningfully to high-quality, cost-effective care throughout the
Premier hospital alliance,, and Surmodics’ growth strategy, are
forward-looking statements. Forward-looking statements involve
inherent risks and uncertainties, and important factors could cause
actual results to differ materially from those anticipated,
including the willingness of Premier members to adopt use of the
Surmodics thrombectomy products, and the factors identified under
“Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K
for the fiscal year ended September 30, 2023, and updated in our
subsequent reports filed with the SEC. These reports are available
in the Investors section of our website at
https://surmodics.gcs-web.com and at the SEC website at
www.sec.gov. Forward-looking statements speak only as of the date
they are made, and we undertake no obligation to update them in
light of new information or future events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240610183584/en/
Surmodics Investor Inquiries: Jack Powell, Investor Relations
ir@surmodics.com
Surmodics Public Relations Inquiries: pr@surmodics.com
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From May 2024 to Jun 2024
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Jun 2023 to Jun 2024